In these studies, the HER2-specific Affibody® molecule with albumin binding domain, ABD-(ZHER2:342)2-Cys, was used which was kindly provided by Affibody Co. through our Cooperative Research and Development Agreement (CRADA). The ABD-HER2-Affibody was conjugated with AlexaFluor 750 with malemide linker (Invitrogen, Eugene, OR). Detail of the conjugation process can be found in (26 (link)). 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (InvivoGen, San Diego, CA), which is known as a heat shock protein 90 (HSP90) inhibitor, was used as therapeutic agent. It is known from the literature (34 (link)-36 (link)) that this drug (like a similar inhibitor 17-AAG) results in HER2 degradation due to HSP90 inhibition.
Protocol detail
HER2-Targeted Theranostic Affibody Probe
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
17 aag
17 dmag
Albumin
Drug
Heat shock protein 90
Her2
Inhibition
Corresponding Organization :
Other organizations : Health and Human Development (2HD) Research Network, Office of Science, National Cancer Institute, The University of Texas MD Anderson Cancer Center
Top 5 similar protocols
Protocol cited in 1 other protocol
Variable analysis
independent variables
- ABD-(ZHER2:342)2-Cys
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG)
- HER2 degradation
- AlexaFluor 750 with malemide linker
- Positive control: Not explicitly mentioned.
- Negative control: Not explicitly mentioned.
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!